{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:12:41Z","timestamp":1789053161612,"version":"build-2803163510"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The present narrative review analyzes the biology of hepatokines as well as their physiological functions and their effect on metabolism and different endocrine-metabolic diseases. Hepatokines are proteins secreted by the liver that play important roles in the regulation of energy homeostasis, inflammation and insulin resistance, behaving as relevant factors in the pathophysiology of pathologies such as obesity, non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. These include FGF21, fetuin-A, selenoprotein P, IGF-1, HGF, and ANGPTL family proteins. In addition, advances in therapies aimed at modulating the action of these proteins, such as FGF21 analogues and ANGPTL3 inhibitors, with good results in NASH resolution, improved insulin sensitivity and serum lipid reduction, are discussed. Molecular pathways related to hepatic signaling, including transcription factors and mechanisms regulating hepatic secretion, are also addressed, opening possibilities for innovative therapeutic strategies. Understanding hepatokines and their mechanisms promotes the development of personalized treatments for metabolic diseases, contributing to improve metabolic health and prevent related complications. This review highlights the importance of integrating liver biology with the clinic to address current challenges in the management of metabolic diseases.<\/jats:p>","DOI":"10.3389\/fendo.2025.1663353","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:33Z","timestamp":1759119153000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["The endocrine role of hepatokines: implications for human health and disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.04.014","article-title":"Adipokines in health and disease","volume":"36","author":"Fasshauer","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/eje.0.1480293","article-title":"The role of the novel adipocyte-derived hormone adiponectin in human disease","volume":"148","author":"D\u00edez","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1210\/endrev\/bnaa016","article-title":"Muscle-organ crosstalk: the emerging roles of myokines","volume":"41","author":"Severinsen","year":"2020","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134490","article-title":"Muscle in endocrinology: from skeletal muscle hormone regulation to myokine secretion and its implications in endocrine\u2013metabolic diseases","volume":"14","author":"Iglesias","year":"2025","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.258","article-title":"The role of hepatokines in metabolism","volume":"9","author":"Stefan","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101138","article-title":"Hepatokines and metabolism: Deciphering communication from the liver","volume":"44","author":"Jensen-Cody","year":"2021","journal-title":"Mol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1154561","article-title":"Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis","volume":"14","author":"Garruti","year":"2023","journal-title":"Front Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0255","article-title":"Identification of hepatokines involved in pathology of type 2 diabetes and obesity","volume":"66","author":"Misu","year":"2019","journal-title":"Endocr J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2016_1252","article-title":"Hepatokines and non-alcoholic fatty liver disease","volume":"63","author":"Lebensztejn","year":"2016","journal-title":"Acta Biochim Pol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02335-9","article-title":"Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation","volume":"61","author":"Miao","year":"2024","journal-title":"Acta Diabetol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0357","article-title":"Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21","volume":"167","author":"Iglesias","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.19-31","article-title":"Selenoprotein P as an in vivo redox regulator: disorders related to its deficiency and excess","volume":"66","author":"Saito","year":"2020","journal-title":"J Clin Biochem Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.01.006","article-title":"The role of hepatokines in NAFLD","volume":"35","author":"Stefan","year":"2023","journal-title":"Cell Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030385","article-title":"Hepatokines as a molecular transducer of exercise","volume":"10","author":"Seo","year":"2021","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081795","article-title":"Identification of the secreted proteins originated from primary human hepatocytes and hepG2 cells","volume":"11","author":"Franko","year":"2019","journal-title":"Nutrients"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c210046","article-title":"Extracellular vesicles in hepatobiliary health and disease","volume":"13","author":"Parthasarathy","year":"2023","journal-title":"Compr Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202404152","article-title":"The endolysosomal system in conventional and unconventional protein secretion","volume":"223","author":"N\u00e9el","year":"2024","journal-title":"J Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094996","article-title":"Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism","volume":"9","author":"Cyphert","year":"2014","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.05.005","article-title":"Regulation of hepatokine gene expression in response to fasting and feeding: Influence of PPAR-\u03b1 and insulin-dependent signaling in hepatocytes","volume":"46","author":"Smati","year":"2020","journal-title":"Diabetes Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.285965","article-title":"Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac088","article-title":"Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease","volume":"107","author":"Dichtel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20020430","article-title":"New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c","volume":"366","author":"Foufelle","year":"2002","journal-title":"Biochem J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1038\/ncomms6190","article-title":"Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors","volume":"5","author":"Haeusler","year":"2014","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00433.2018","article-title":"Role of exercise-induced hepatokines in metabolic disorders","volume":"317","author":"Ennequin","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052639","article-title":"Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions","volume":"22","author":"de Oliveira Dos Santos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073959","article-title":"Hepatic PTEN signaling regulates systemic metabolic homeostasis through hepatokines-mediated liver-to-peripheral organs crosstalk","volume":"23","author":"Berthou","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1567-5769(02)00058-9","article-title":"The role of NF-kappaB in the regulation of cell stress responses","volume":"2","author":"Wang","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/1566524020666201026162343","article-title":"Critical role of NF\u03baB in the pathogenesis of non-alcoholic fatty liver disease: A widespread key regulator","volume":"21","author":"Franceschetti","year":"2021","journal-title":"Curr Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1352.026","article-title":"Transcription factor NF-kappaB: a sensor for smoke and stress signals","volume":"1056","author":"Ahn","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30252","article-title":"Contribution of organokines in the development of NAFLD\/NASH associated hepatocellular carcinoma","volume":"123","author":"Vachher","year":"2022","journal-title":"J Cell Biochem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.10.030","article-title":"Hepatokines and adipokines in NASH-related hepatocellular carcinoma","volume":"74","author":"Kucukoglu","year":"2021","journal-title":"J Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071816-064800","article-title":"Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis","volume":"38","author":"BonDurant","year":"2018","journal-title":"Annu Rev Nutr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21-metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00101.2017","article-title":"Fibroblast growth factor 21: a regulator of metabolic disease and health span","volume":"313","author":"Xie","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113318","article-title":"Liver brain interactions: focus on FGF21 a systematic review","volume":"23","author":"Prida","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/154575a0","article-title":"Fetuin, a new globulin isolated from serum","volume":"154","author":"Pedersen","year":"1944","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2174\/156652412800620039","article-title":"Anti-inflammatory role of fetuin-A in injury and infection","volume":"12","author":"Wang","year":"2012","journal-title":"Curr Mol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2019.1631751","article-title":"Effects of nutritional status on serum fetuin-A level","volume":"60","author":"Icer","year":"2020","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2000.1735","article-title":"Selenoprotein P: properties, functions, and regulation","volume":"376","author":"Mostert","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.24.012003.132120","article-title":"Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis","volume":"25","author":"Burk","year":"2005","journal-title":"Annu Rev Nutr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.08.022","article-title":"Selenoprotein P - Selenium transport protein, enzyme and biomarker of selenium status","volume":"191","author":"Schomburg","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140353","article-title":"Regulation of selenocysteine content of human selenoprotein P by dietary selenium and insertion of cysteine in place of selenocysteine","volume":"10","author":"Turanov","year":"2015","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b19-00837","article-title":"Selenoprotein P; P for plasma, prognosis, prophylaxis, and more","volume":"43","author":"Tsutsumi","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"B49","article-title":"A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro","volume":"49","author":"Salmon","year":"1957","journal-title":"J Lab Clin Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1210\/er.2009-0010","article-title":"The role of liver-derived insulin-like growth factor-I","volume":"30","author":"Ohlsson","year":"2009","journal-title":"Endocr Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00212.2016","article-title":"Defining human insulin-like growth factor I gene regulation","volume":"311","author":"Mukherjee","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-224","article-title":"Human conditions of insulin-like growth factor-I (IGF-I) deficiency","volume":"10","author":"Puche","year":"2012","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1159\/000527123","article-title":"The history of the insulin-like growth factor system","volume":"95","author":"Miller","year":"2022","journal-title":"Horm Res Pediatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00649-8","article-title":"Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis","volume":"18","author":"Mazziotti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4012","article-title":"Idiopathic adult growth hormone deficiency","volume":"98","author":"Melmed","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(84)91253-1","article-title":"Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats","volume":"122","author":"Nakamura","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1991.tb00897.x","article-title":"Hepatocyte growth factor: molecular structure and implications for a central role in liver regeneration","volume":"6","author":"Matsumoto","year":"1991","journal-title":"J Gastroenterol Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07637.x","article-title":"Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor","volume":"277","author":"Miyazawa","year":"2010","journal-title":"FEBS J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1440-1746.2010.06549.x","article-title":"Hepatocyte growth factor twenty years on: Much more than a growth factor","author":"Nakamura","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113435","article-title":"Hepatocyte growth factor activator: A proteinase linking tissue injury with repair","volume":"19","author":"Fukushima","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B61","first-page":"8","article-title":"Purification and characterization of hepatocyte growth factor from injured liver of carbon tetrachloride-treated rats","volume":"109","author":"Asami","year":"1991","journal-title":"J Biochem (Tokyo)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.02.030","article-title":"Molecular process in acute liver injury and regeneration induced by carbon tetrachloride","volume":"75","author":"Taniguchi","year":"2004","journal-title":"Life Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(97)00744-8","article-title":"Continuous hepatocyte growth factor supply prevents lipopolysaccharide-induced liver injury in rats","volume":"411","author":"Kaido","year":"1997","journal-title":"FEBS Lett"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e82159","DOI":"10.1371\/journal.pone.0082159","article-title":"The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation","volume":"8","author":"Harvey","year":"2013","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.808855","article-title":"HGF\/c-met: A key promoter in liver regeneration","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/aps.2010.90","article-title":"Hepatocyte growth factor in lung repair and pulmonary fibrosis","volume":"32","author":"Panganiban","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"B67","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41598-017-00199-4","article-title":"Hepatocyte growth factor prevented high-fat diet-induced obesity and improved insulin resistance in mice","volume":"7","author":"Muratsu","year":"2017","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00914","article-title":"Hepatocyte growth factor regulates macrophage transition to the M2 phenotype and promotes murine skeletal muscle regeneration","volume":"10","author":"Choi","year":"2019","journal-title":"Front Physiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673320024240829070906","article-title":"ANGPTL4-the link binding lipid metabolism and inflammation","volume":"32","author":"Zhang","year":"2025","journal-title":"Curr Med Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171185","article-title":"Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation","volume":"12","author":"Massafra","year":"2017","journal-title":"PloS One"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.diff.2024.100816","article-title":"A primer on the pleiotropic endocrine fibroblast growth factor FGF19\/FGF15","volume":"140","author":"Bouju","year":"2024","journal-title":"Differ Res Biol Divers"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102442","article-title":"Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma","volume":"298","author":"Chu","year":"2022","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156697","article-title":"Updates on the role of leukocyte cell-derived chemotaxin-2 in inflammation regulation and immunomodulation","volume":"181","author":"Lao","year":"2024","journal-title":"Cytokine"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3634-4","article-title":"Hepatokines: unlocking the multi-organ network in metabolic diseases","volume":"58","author":"Iroz","year":"2015","journal-title":"Diabetologia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010498","article-title":"Non-alcoholic steatohepatitis (NASH) and organokines: what is now and what will be in the future","volume":"23","author":"Santos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatol Baltim Md"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177356","article-title":"Hepatokines and their role in cardiohepatic interactions in heart failure","volume":"992","author":"Shouman","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.108102","article-title":"Fetuin-A to adiponectin ratio is an independent indicator of subclinical atherosclerosis in patients with newly diagnosed type 2 diabetes mellitus","volume":"36","author":"Zhou","year":"2022","journal-title":"J Diabetes Complications"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1108234","article-title":"Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis","volume":"14","author":"Yan","year":"2023","journal-title":"Front Endocrinol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2015.10.010","article-title":"Progression and natural history of nonalcoholic fatty liver disease in adults","volume":"20","author":"Marengo","year":"2016","journal-title":"Clin Liver Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: consider the population","author":"Mittal","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J Hepatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1281","article-title":"Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK biobank","volume":"80","author":"Knuppel","year":"2020","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad212","article-title":"IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-heidelberg","volume":"108","author":"Mukama","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B87","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3892\/mmr.2025.13574","article-title":"Insulin\u2212like growth factor in cancer: New perspectives (Review)","volume":"32","author":"Wu","year":"2025","journal-title":"Mol Med Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.014","article-title":"IGF1\/IGF1R\/STAT3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis","volume":"393","author":"Xu","year":"2017","journal-title":"Cancer Lett"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8234","article-title":"IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1\/STAT3 signaling pathway","volume":"15","author":"Su","year":"2018","journal-title":"Oncol Lett"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12733","article-title":"IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process","volume":"7","author":"Le Coz","year":"2016","journal-title":"Oncotarget"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103534","article-title":"IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion","volume":"9","author":"Sarkissyan","year":"2014","journal-title":"PloS One"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s12672-025-02890-9","article-title":"IGF1\/IGF1R signaling promotes the expansion of liver CSCs and serves as a potential therapeutic target in HCC","volume":"16","author":"Tian","year":"2025","journal-title":"Discov Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-02970-8","article-title":"IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis","volume":"43","author":"Yang","year":"2024","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.01.005","article-title":"The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer","volume":"87","author":"Anisimov","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0394","article-title":"Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome","volume":"30","author":"Laron","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J","article-title":"Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis","volume":"183","author":"Grimberg","year":"2000","journal-title":"J Cell Physiol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914882","article-title":"The IGF1 signaling pathway: from basic concepts to therapeutic opportunities","volume":"24","author":"Werner","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s1470-2045(02)00731-3","article-title":"Insulin-like growth factors and cancer","volume":"3","author":"F\u00fcrstenberger","year":"2002","journal-title":"Lancet Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.18.1472","article-title":"Role of the insulin-like growth factor family in cancer development and progression","volume":"92","author":"Yu","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5715","article-title":"Emerging roles of angiopoietin\u2212like 4 in human tumors (Review)","volume":"66","author":"Liu","year":"2025","journal-title":"Int J Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312918","article-title":"The role of fetuin-A in tumor cell growth, prognosis, and dissemination","volume":"25","author":"Odiase","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.967375","article-title":"The role of FGF21 and its analogs on liver associated diseases","volume":"9","author":"Falamarzi","year":"2022","journal-title":"Front Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122033","article-title":"Pathophysiological implication of fetuin-A glycoprotein in the development of metabolic disorders: A concise review","volume":"8","author":"Bourebaba","year":"2019","journal-title":"J Clin Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.873699","article-title":"Adipokines, hepatokines and myokines: focus on their role and molecular mechanisms in adipose tissue inflammation","volume":"13","author":"Ren","year":"2022","journal-title":"Front Endocrinol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"21424","DOI":"10.1038\/s41598-023-48565-9","article-title":"Pigment epithelium-derived factor (PEDF) represses the glucose transporter 1 (GLUT1) mRNA expression and may be a potential therapeutic agent in psoriasis: a case-control and experimental study","volume":"13","author":"Mohany","year":"2023","journal-title":"Sci Rep"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01239.2003","article-title":"Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts","volume":"288","author":"Nakamura","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1089214","article-title":"The potential function and clinical application of FGF21 in metabolic diseases","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14468","article-title":"Insulin-like growth factor-1, growth hormone and disease outcomes in acromegaly: A population study","volume":"95","author":"Thomas","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03447-y","article-title":"Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study","volume":"82","author":"Xiao","year":"2023","journal-title":"Endocrine"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0287","article-title":"Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of Malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database)","volume":"95","author":"Popovic","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1594091","article-title":"A systematic review and meta-analysis of efruxifermin\u2019s efficacy in improving liver fibrosis in patients with NASH\/MASH","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/cpt.3278","article-title":"Efficacy and safety of fibroblast growth factor-21 analogs for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis","volume":"116","author":"Jeong","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicenter, randomized, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001618","article-title":"The novel glycoPEGylated FGF21 analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers","volume":"387","author":"Rosenstock","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101688","article-title":"Angiopoietin-like 3: An important protein in regulating lipoprotein levels","volume":"37","author":"Burks","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000755","article-title":"Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia","volume":"32","author":"Mohamed","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01071-1","article-title":"ANGPTL3 as a drug target in hyperlipidemia and atherosclerosis","volume":"24","author":"Mohamed","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2047934","article-title":"Evinacumab for the treatment of homozygous familial hypercholesterolemia","volume":"15","author":"Gao","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13836","article-title":"Evinacumab: Mechanism of action, clinical, and translational science","volume":"17","author":"Dingman","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV22038","article-title":"ANGPTL3: A breakthrough target in treatment for dyslipidemia and atherosclerosis","volume":"32","author":"Fukami","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1663353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:34Z","timestamp":1759119154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1663353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":127,"alternative-id":["10.3389\/fendo.2025.1663353"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1663353","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1663353"}}